DK0971033T3 - Test og model til Alzheimers sygdom - Google Patents

Test og model til Alzheimers sygdom

Info

Publication number: DK0971033T3
Authority: DK; Denmark
Prior art keywords: alzheimer; amino acid; disease; model; test
Prior art date: 1991-01-21

Application number

DK99109196T

Other languages

English (en)

Inventor

Michael John Owen

John Anthony Hardy

Marie-Christine Chartier-Harlin

Alison Mary Goate

Michael John Mullan

Original Assignee

Elan Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-21

Filing date

1992-01-21

Publication date

2009-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0971033(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-01-21 Priority claimed from GB919101307A external-priority patent/GB9101307D0/en

1991-08-28 Priority claimed from GB919118445A external-priority patent/GB9118445D0/en

1992-01-21 Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc

2009-12-14 Application granted granted Critical

2009-12-14 Publication of DK0971033T3 publication Critical patent/DK0971033T3/da

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
208000034826 Genetic Predisposition to Disease Diseases 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Environmental Sciences (AREA)
Analytical Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Plant Pathology (AREA)
Pathology (AREA)
Biodiversity & Conservation Biology (AREA)
Immunology (AREA)
Animal Husbandry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)

DK99109196T 1991-01-21 1992-01-21 Test og model til Alzheimers sygdom DK0971033T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB919101307A GB9101307D0 (en)	1991-01-21	1991-01-21	Test for alzheimers disease
GB919118445A GB9118445D0 (en)	1991-08-28	1991-08-28	Test for alzheimer's disease
PCT/GB1992/000123 WO1992013069A1 (en)	1991-01-21	1992-01-21	Test and model for alzheimer's disease

Publications (1)

Publication Number	Publication Date
DK0971033T3 true DK0971033T3 (da)	2009-12-14

Family

ID=26298303

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK92903304.1T DK0568575T4 (da)	1991-01-21	1992-01-21	Test og model for Alzheimers sygdom
DK99109196T DK0971033T3 (da)	1991-01-21	1992-01-21	Test og model til Alzheimers sygdom

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK92903304.1T DK0568575T4 (da)	1991-01-21	1992-01-21	Test og model for Alzheimers sygdom

Country Status (10)

Country	Link
US (3)	US5877015A (da)
EP (2)	EP0568575B2 (da)
JP (3)	JP3510244B2 (da)
AT (2)	ATE286971T1 (da)
AU (1)	AU652997B2 (da)
CA (2)	CA2372251A1 (da)
DE (3)	DE971033T1 (da)
DK (2)	DK0568575T4 (da)
ES (2)	ES2335720T3 (da)
WO (1)	WO1992013069A1 (da)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2372251A1 (en)	1991-01-21	1992-08-06	Michael John Mullan	Test and model for alzheimer's disease
EP0613560B2 (en) *	1991-11-12	2006-06-21	Prana Biotechnology Ltd	A method for assaying and treating alzheimer's disease
AU3249793A (en) *	1991-12-24	1993-07-28	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating beta -amyloid
JPH07506720A (ja) *	1992-01-07	1995-07-27	アテナ　ニューロサイエンシーズ，　インコーポレイテッド	アルツハイマー病のトランスジェニック動物モデル
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
US5455169A (en) *	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US6610493B1 (en)	1993-06-17	2003-08-26	Brigham And Women's Hospital	Screening compounds for the ability to alter the production of amyloid-β peptide
US6328971B1 (en) *	1993-01-22	2001-12-11	Ludwig Institute For Cancer Research	MAGE-1 derived nona peptides, and compositions thereof
JPH09507746A (ja)	1993-10-27	1997-08-12	アテナニューロサイエンシズ，インコーポレイティド	Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
US5877399A (en)	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0742831B1 (en)	1994-01-27	2004-09-29	The Regents Of The University Of Minnesota	Transgenic non-human mammals with progressive neurologic disease
JPH10504964A (ja) *	1994-09-01	1998-05-19	メルクエンドカンパニーインコーポレーテッド	家族性型ヒトアミロイド前駆タンパク質を発現するトランスジェニック動物
US6187992B1 (en)	1994-12-05	2001-02-13	Merck & Co., Inc.	Transgenic mouse having a disrupted amyloid precursor protein gene
US5674681A (en) *	1994-12-06	1997-10-07	Rothenberg; Barry E.	Methods to identify hemochromatosis
JP2001517065A (ja) *	1995-06-07	2001-10-02	アセナニューロサイエンシーズ，インコーポレイテッド	トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
AUPN649395A0 (en) *	1995-11-10	1995-12-07	Ramsay Health Care Pty Ltd	A method for diagnosing alzheimer's disease
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
CA2183901A1 (en) *	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6933331B2 (en) *	1998-05-22	2005-08-23	Nanoproducts Corporation	Nanotechnology for drug delivery, contrast agents and biomedical implants
US5898094A (en) *	1996-10-21	1999-04-27	University Of South Florida	Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
ES2128265B1 (es) *	1997-06-04	2000-03-01	Euroespes S A	Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
JP2001521043A (ja) *	1997-10-24	2001-11-06	アバンテイス・フアルマ・エス・アー	プレセニリンとβ−アミロイドペプチドまたはその前駆体との相互作用を阻害し得るペプチド
FR2770217B1 (fr) *	1997-10-24	2001-12-07	Rhone Poulenc Rorer Sa	Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6844148B1 (en) *	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
KR20070013361A (ko)	1998-09-24	2007-01-30	파마시아 앤드 업존 캄파니 엘엘씨	알츠하이머병 세크레타제
US6699671B1 (en)	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7115410B1 (en) *	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
JP4653318B2 (ja)	1999-02-10	2011-03-16	エランファーマシューティカルズ，インコーポレイテッド	βセクレターゼ酵素組成物および方法
US6355425B1 (en)	1999-03-26	2002-03-12	Billups-Rothenberg, Inc.	Mutations associated with iron disorders
US7056661B2 (en) *	1999-05-19	2006-06-06	Cornell Research Foundation, Inc.	Method for sequencing nucleic acid molecules
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US20090162883A1 (en) *	1999-09-23	2009-06-25	Pharmacia & Upjohn Company	Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US6310048B1 (en)	1999-12-09	2001-10-30	St. Louis University	Antisense modulation of amyloid beta protein expression
CA2395926A1 (en) *	1999-12-28	2001-07-05	Curagen Corporation	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
JP2003528071A (ja) *	2000-03-23	2003-09-24	エランファーマスーティカルズインコーポレイテッド	アルツハイマー病治療用組成物および方法
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
JP2004502665A (ja) *	2000-06-30	2004-01-29	イーラン　ファーマスーティカルズ、インコーポレイテッド	アルツハイマー病を治療する化合物
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
EP1666452A2 (en)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
AU2001269127A1 (en) *	2000-07-06	2002-01-14	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	A novel app mutation associated with an unusual alzheimer's disease pathology
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
WO2002098849A2 (en) *	2001-06-01	2002-12-12	Elan Pharmaceuticals, Inc.	Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
WO2002100818A2 (en)	2001-06-13	2002-12-19	Elan Pharmaceuticals, Inc.	Aminediols as agents for the treatment of alzheimer's disease
WO2003002122A1 (en) *	2001-06-27	2003-01-09	Elan Pharmaceuticals, Inc.	Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
US20070213407A1 (en) *	2001-06-29	2007-09-13	Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc	Compounds to treat Alzheimer's disease
WO2003006013A1 (en) *	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Diaminediols for the treatment of alzheimer's disease
WO2003006453A1 (en) *	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Aminediols for the treatment of alzheimer's disease
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
US7244755B2 (en)	2001-10-04	2007-07-17	Pharmacia & Upjohn Company	Hydroxypropylamines
RS50504A (sr) *	2001-11-08	2007-04-10	Elan Pharmaceuticals Inc.,	Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana
CA2467476A1 (en) *	2001-11-19	2003-05-30	Pharmacia & Upjohn Company	Amino diols useful in the treatment of alzheimer's disease
US20040016008A1 (en) *	2002-01-07	2004-01-22	Brimijoin William Stephen	Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
CA2477002A1 (en) *	2002-02-27	2003-09-04	Merck & Co., Inc.	Assays to monitor amyloid precursor protein processing
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
WO2004058686A1 (en) *	2002-04-30	2004-07-15	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of alzheimer’s disease
UY27967A1 (es) *	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
JP2006508166A (ja) *	2002-11-27	2006-03-09	イーランファーマスーティカルズ、インコーポレイテッド	置換尿素及びカルバメート
MXPA05008156A (es)	2003-02-01	2005-09-30	Neuralab Ltd	Inmunizacion activa para generar anticuerpos para beta-a soluble.
MXPA05011150A (es) *	2003-04-21	2005-12-14	Elan Pharm Inc	2-hidroxi-3-diaminoalcanos de benzamida.
CA2522805A1 (en) *	2003-04-21	2004-11-04	Elan Pharmaceuticals, Inc.	Phenacyl 2-hydroxy-3-diaminoalkanes
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20050009110A1 (en) *	2003-07-08	2005-01-13	Xiao-Jia Chang	Methods of producing antibodies for diagnostics and therapeutics
WO2005010039A1 (en) *	2003-07-31	2005-02-03	Pfizer Products Inc.	Bsep polypeptide variants and uses thereof
CA2553973A1 (en) *	2004-01-21	2005-08-04	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using aspartyl-protease inihibitors
US20050239832A1 (en) *	2004-03-09	2005-10-27	Varghese John	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
EP1735293A2 (en) *	2004-03-09	2006-12-27	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
CA2558034A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
US20050261273A1 (en) *	2004-03-09	2005-11-24	Varghese John	Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
US7544855B2 (en) *	2004-04-23	2009-06-09	Buck Institute	Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
CA2567223A1 (en) *	2004-05-19	2005-11-24	Boehringer Ingelheim International Gmbh	Treatment of diseases associated with altered level of amyloid beta peptides
JP2008505929A (ja) *	2004-07-09	2008-02-28	エランファーマシューティカルズ，インコーポレイテッド	オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US7385085B2 (en) *	2004-07-09	2008-06-10	Elan Pharmaceuticals, Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) *	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
CA2577392A1 (en) *	2004-08-27	2006-03-09	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
BRPI0517672A (pt) *	2004-11-05	2008-10-14	Wyeth Corp	modalidades de formação de imagens para seleção terapêutica de doença de alzheimer
ES2396555T3 (es)	2004-12-15	2013-02-22	Janssen Alzheimer Immunotherapy	Anticuerpos que reconocen péptido beta amiloide
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
US20090124993A1 (en)	2005-02-17	2009-05-14	Burkly Linda C	Treating neurological disorders
JP4853892B2 (ja) *	2005-04-13	2012-01-11	独立行政法人国立精神・神経医療研究センター	変異対立遺伝子に対する特異的なＲＮＡｉの評価方法
WO2006122187A2 (en)	2005-05-10	2006-11-16	Biogen Idec Ma Inc.	Treating and evaluating inflammatory disorders
GB0511861D0 (en) *	2005-06-13	2005-07-20	Merck Sharp & Dohme	Proteins
EP1746092A1 (en)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Compounds and methods for treatment of amyloid-B-peptide related disorders
CA2617294A1 (en) *	2005-08-03	2007-02-08	Boehringer Ingelheim International Gmbh	Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
JP2009504611A (ja) *	2005-08-11	2009-02-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	アルツハイマー病の治療用β−セクレターゼインヒビター
US20090042867A1 (en) *	2005-08-11	2009-02-12	Klaus Fuchs	Compounds for the treatment of alzheimer's disease
JP2009504614A (ja) *	2005-08-11	2009-02-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	アルツハイマー病の治療用化合物
CA2618474A1 (en) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Compounds for treating alzheimer's disease
CA2624904A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007092846A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7868022B2 (en)	2006-02-06	2011-01-11	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2007092839A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
CA2653628C (en)	2006-06-01	2015-07-14	Elan Pharmaceuticals, Inc.	Neuroactive fragments of app
KR101495549B1 (ko)	2006-07-13	2015-02-25	와이어쓰 엘엘씨	당단백질의 생산
KR101608445B1 (ko)	2006-10-12	2016-04-01	비에이치아이 리미티드 파트너쉽	3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
US8192951B2 (en)	2006-11-03	2012-06-05	Wyeth Llc	Glycolysis-inhibiting substances in cell culture
RU2009132986A (ru)	2007-03-02	2011-04-10	Уайт (Us)	Применение меди и глутамата в культуре клеток для производства полипептидов
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US8466118B2 (en) *	2007-04-23	2013-06-18	Saint Louis University	Modulation of blood brain barrier protein expression
KR101730290B1 (ko)	2007-05-11	2017-04-25	토마스 제퍼슨 유니버시티	신경변성 질환 및 장애의 치료 및 예방 방법
JP5450407B2 (ja)	2007-07-06	2014-03-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
NZ586831A (en) *	2008-01-28	2012-02-24	Janssen Pharmaceutica Nv	6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
EP2240472B1 (en) *	2008-01-29	2012-11-21	Janssen Pharmaceutica NV	2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
WO2009105572A2 (en) *	2008-02-19	2009-08-27	Edunn Biotechonology Inc.	Antisense modulation of amyloid beta protein expression
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US20110023152A1 (en) *	2008-12-04	2011-01-27	Sigma-Aldrich Co.	Genome editing of cognition related genes in animals
AU2011291506B2 (en)	2010-08-19	2016-07-28	Buck Institute For Age Research	Methods of treating mild cognitive impairment (mci) and related disorders
USRE49873E1 (en)	2012-03-19	2024-03-19	Buck Institute For Research On Aging	APP specific bace inhibitors (ASBIs) and uses thereof
US9421245B2 (en)	2012-06-25	2016-08-23	The Brigham And Women's Hospital, Inc.	Targeted therapeutics
WO2014127042A1 (en)	2013-02-12	2014-08-21	Buck Institute For Research On Aging	Hydantoins that modulate bace-mediated app processing
US9937231B2 (en)	2013-03-27	2018-04-10	The General Hospital Corporation	Methods and agents for treating Alzheimer's disease
KR101890978B1 (ko)	2014-06-17	2018-08-24	서울대학교산학협력단	알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
US10683552B2 (en)	2014-11-25	2020-06-16	Presidents And Fellows Of Harvard College	Clonal haematopoiesis
US11168369B2 (en)	2014-11-25	2021-11-09	The Brigham And Women's Hospital, Inc.	Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
KR20180090778A (ko)	2015-08-27	2018-08-13	난트뉴로, 엘엘씨	App-선택적 bace 억제를 위한 조성물 및 그의 용도
CA3024067C (en)	2016-05-12	2024-04-09	Buck Institute For Research On Aging	Compounds to promote normal processing of app

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4492760A (en) *	1983-04-19	1985-01-08	The Wistar Institute Of Anatomy And Biology	HLA D Typing assay
JPS6147500A (ja) *	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en) *	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja) *	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) *	1985-10-28	1987-05-09	Teijin Ltd	遺伝子断片およびプラスミド
EP0247091B1 (en) *	1985-11-01	1993-09-29	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
DE3702789A1 (de) *	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
WO1989006689A1 (en) *	1988-01-13	1989-07-27	The Mclean Hospital Corporation	Genetic constructs containing the alzheimer brain amyloid gene
US5134062A (en) *	1988-03-22	1992-07-28	Cornell Research Foundation, Inc.	Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
DE3907562A1 (de)	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
EP0471796A4 (en)	1989-05-10	1993-05-05	Sloan Kettering Institute For Cancer Research	Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5234814A (en) *	1989-06-01	1993-08-10	Du Pont Merck Pharmaceutical Company	Diagnostic assay for alzheimer's disease
WO1991004753A1 (en)	1989-10-02	1991-04-18	Cetus Corporation	Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5180819A (en)	1989-12-22	1993-01-19	The Trustees Of Columbia University In The City Of New York	Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
EP0451700A1 (en) *	1990-04-10	1991-10-16	Miles Inc.	Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
CA2079880A1 (en) *	1990-04-24	1991-10-25	William E. Van Nostrand	Purification, detection and methods of use of protease nexin-2
WO1991019810A1 (en) *	1990-06-15	1991-12-26	California Biotechnology Inc.	Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
WO1992000521A1 (en) *	1990-06-29	1992-01-09	Case Western Reserve University	Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) *	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) *	1990-11-27	1992-02-25	Will L F & Cie Sa	Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
CA2372251A1 (en)	1991-01-21	1992-08-06	Michael John Mullan	Test and model for alzheimer's disease
WO1993007296A1 (en) *	1991-10-03	1993-04-15	Indiana University Foundation	Method for screening for alzheimer's disease
JPH07506720A (ja) *	1992-01-07	1995-07-27	アテナ　ニューロサイエンシーズ，　インコーポレイテッド	アルツハイマー病のトランスジェニック動物モデル
US5604102A (en) *	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US7371129B2 (en)	2005-04-27	2008-05-13	Samtec, Inc.	Elevated height electrical connector

1992
- 1992-01-21 CA CA002372251A patent/CA2372251A1/en not_active Abandoned
- 1992-01-21 EP EP92903304A patent/EP0568575B2/en not_active Expired - Lifetime
- 1992-01-21 EP EP99109196A patent/EP0971033B1/en not_active Revoked
- 1992-01-21 ES ES99109196T patent/ES2335720T3/es not_active Expired - Lifetime
- 1992-01-21 ES ES92903304T patent/ES2236682T5/es not_active Expired - Lifetime
- 1992-01-21 US US08/104,165 patent/US5877015A/en not_active Expired - Lifetime
- 1992-01-21 DK DK92903304.1T patent/DK0568575T4/da active
- 1992-01-21 AT AT92903304T patent/ATE286971T1/de not_active IP Right Cessation
- 1992-01-21 AU AU11694/92A patent/AU652997B2/en not_active Expired
- 1992-01-21 AT AT99109196T patent/ATE447016T1/de not_active IP Right Cessation
- 1992-01-21 DE DE0971033T patent/DE971033T1/de active Pending
- 1992-01-21 JP JP50357592A patent/JP3510244B2/ja not_active Expired - Lifetime
- 1992-01-21 WO PCT/GB1992/000123 patent/WO1992013069A1/en not_active Ceased
- 1992-01-21 DE DE69233774T patent/DE69233774D1/de not_active Expired - Lifetime
- 1992-01-21 CA CA2101774A patent/CA2101774C/en not_active Expired - Lifetime
- 1992-01-21 DK DK99109196T patent/DK0971033T3/da active
- 1992-01-21 DE DE69233468T patent/DE69233468T3/de not_active Expired - Lifetime
1995
- 1995-06-05 US US08/464,250 patent/US6300540B1/en not_active Expired - Lifetime
2001
- 2001-12-27 JP JP2001397308A patent/JP3574432B2/ja not_active Expired - Lifetime
2003
- 2003-02-03 US US10/357,935 patent/US20030165958A1/en not_active Abandoned
2004
- 2004-04-30 JP JP2004136760A patent/JP2004261187A/ja active Pending

Also Published As

Publication number	Publication date
DK0568575T3 (da)	2005-05-23
US6300540B1 (en)	2001-10-09
EP0568575A1 (en)	1993-11-10
DE69233468T3 (de)	2011-05-05
JP2002306195A (ja)	2002-10-22
US20030165958A1 (en)	2003-09-04
US5877015A (en)	1999-03-02
CA2101774C (en)	2011-01-04
AU652997B2 (en)	1994-09-15
DE971033T1 (de)	2001-05-03
EP0971033A3 (en)	2003-11-12
ES2335720T3 (es)	2010-03-31
ATE286971T1 (de)	2005-01-15
ES2236682T5 (es)	2011-03-31
EP0568575B2 (en)	2010-11-03
DE69233774D1 (de)	2009-12-10
AU1169492A (en)	1992-08-27
JPH06504441A (ja)	1994-05-26
ES2236682T3 (es)	2005-07-16
JP2004261187A (ja)	2004-09-24
CA2101774A1 (en)	1992-07-22
EP0568575B1 (en)	2005-01-12
DE69233468D1 (de)	2005-02-17
JP3510244B2 (ja)	2004-03-22
ATE447016T1 (de)	2009-11-15
WO1992013069A1 (en)	1992-08-06
CA2372251A1 (en)	1992-08-06
EP0971033B1 (en)	2009-10-28
EP0971033A2 (en)	2000-01-12
JP3574432B2 (ja)	2004-10-06
DE69233468T2 (de)	2005-12-22
DK0568575T4 (da)	2010-12-20

Publication	Publication Date	Title
DK0568575T3 (da)	2005-05-23	Test og model for Alzheimers sygdom
DK0994728T3 (da)	2008-12-01	Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
NO308029B1 (no)	2000-07-10	Inhibitorer av <beta>-amyloidproteinproduksjon og farmasøytisk preparat inneholdende disse
ES2187516T3 (es)	2003-06-16	Quimioquina novedosa producida por las celulas hematopoyeticas y adn que codifica dicha quimioquina.
NO931889D0 (no)	1993-05-25	Protease og beslektede dna-forbindelser
DK169724B1 (da)	1995-01-23	Fremgangsmåde til fremstilling af et polypeptidfragment af faktor VIII:C, DNA-sekvens, som koder herfor, og ekstrachromosomalt element indeholdende en sådan DNA-sekvens
DK1093517T3 (da)	2008-06-23	Neisseria-meningitidis-antigener og præparater
EP0670731A4 (en)	1997-06-11	TREATMENT OF AMNESIA DUE TO THE DEPOSITION OF THE AMYLOID PROTEIN -g (b) IN ALZHEIMER'S DISEASE.
DK0868519T3 (da)	2006-05-08	Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
DE69535274D1 (de)	2006-11-30	Verwendung eines menschlichen interleukin-11 rezeptors
EP0205475A4 (en)	1990-06-27	RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF.
DK0948604T3 (da)	2004-11-22	Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DK1330656T3 (da)	2008-08-11	Midler til detektion af patologiske transformationer af proteinet APP og anvendelser heraf
ATE417930T1 (de)	2009-01-15	Proteinkinase npk-110
DK610888A (da)	1988-11-02	Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
DE68925275D1 (de)	1996-02-08	Endotoxin-bindeprotein und dessen verwendung
EP0716591A4 (en)	1998-02-04	METHODS AND COMPOSITIONS FOR BINDING TAU AND MAP2c PROTEINS
FI822065A7 (fi)	1982-12-24	Menetelmä aspartiinihapon ja glutamiinihapon täydelliseksi tai osittaiseksi poistamiseksi proteiiniproteiinihydrolyysisaasteista ja aminohapposeoksista sekä näin saadut aminohapposeokset.
DE3856364D1 (de)	1999-11-04	Verarbeitungssystem zur Fehlerinformationssammlung
DK450187D0 (da)	1987-08-28	Fremgangsmaade til fremstilling af proteiner
ATE315582T1 (de)	2006-02-15	Verwendung von neuregulin-beta als indikator und/oder target
MX9304839A (es)	1994-02-28	Marcador para determinar la inclusion de un bovino en un programa de cria.
DE69734890D1 (de)	2006-01-19	Rdgb-proteine
DK0972781T3 (da)	2007-03-05	Protein S-polypeptider og anvendelser deraf
DK1129191T3 (da)	2006-07-17	Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme